CA-ALATION/BIGEYE/SODA
7.12.2021 15:02:09 CET | Business Wire | Press release
Alation, Inc. , the leader in enterprise data intelligence solutions, today announced formal partnership agreements with Bigeye and Soda , leading data observability vendors. The partnerships provide customers with the choice to select the best data observability partner for their organisation’s needs.
Alation’s active data governance helps organisations drive data culture by providing all data users, regardless of technical skillset, with access to quality data. Bigeye’s data observability platform helps detect data quality issues and ensures reliable data pipelines. Soda’s data observability platform allows teams to discover, prioritise, and collaboratively resolve data issues. The platforms are invaluable for alerting technical users to deeper data quality issues, such as the trustworthiness of the data or its usability. Alation’s integrations with Bigeye and Soda provide all data consumers, from business users to data scientists, with a single-pane-of-glass view into the trustworthiness and reliability of data. This results in a streamlined analysis process that empowers data users to use data and generate insights with confidence.
“When it comes to data intelligence and data governance, Alation has long catered to the needs of every user, not just the technical user. Our customers see Alation as the primary source of reference for all metadata, which enables all teams across an organisation to make data-driven business decisions,” said Raj Gossain, Chief Product Officer, Alation. “The Alation Data Catalog is a platform known for its interoperability. With our APIs and partnerships, we continue to expand the ecosystem of companies that work with Alation, giving our customers a modern user experience that seamlessly integrates best-of-breed solutions that meet their needs.”
Fuelled by exponential data growth and expanding privacy regulations, data governance is a top priority for enterprises. Traditional approaches to data governance have long focused on restrictive data policies and procedures that hinder adoption and result in additional challenges for those responsible for the data. Effective data governance programs must focus on enabling users to leverage trusted, governed data to make informed, data-driven decisions. Organisations using an active, people-first approach to data governance, drive data culture and put quality data, not just any data, in everyone’s hands.
“A key part of ensuring data quality and reliable data pipelines is the ability to keep data teams and data consumers on the same page. With the integration between Alation and Bigeye, everyone — from data engineers all the way to business analysts — has a clear understanding of the health of the data,” said Egor Gryaznov, CTO and cofounder, Bigeye. “Pairing the leading data observability platform with Alation’s leading data catalog provides organisations with a holistic view of the quality of their data.”
“The modern data catalog is becoming a real-time, operational system that's deeply tied into an organisation’s data ecosystem. For metadata, that means it is purposefully built into every step of the data value chain, as opposed to it being an afterthought. This allows data teams to truly see what's happening so that they can catch data issues before they reach consumers downstream,” explains Maarten Masschelein, CEO and Co-Founder, Soda. “Through our partnership with Alation, users can discover and understand the data that matters to them, and trust they are working with data that is verified, reliable, and governed. Soda enables data producers and consumers to agree on what good data looks like by combining both machine learning-based alerting, as well as rules-based testing and validation of data. Every single operational metadata quality issue that Soda captures, can be made natively available in the Alation Data Catalog. We layer our data quality controls on top of Alation’s automated lineage to make it easy to do Root Cause Analysis (RCA), as well as assess the upstream and downstream impact of a data issue.”
To learn more about Alation’s partnerships with Bigeye and Soda:
- Read the blog: Alation & Bigeye: A Potent Partnership for Data Quality
- Read the blog: Alation & Soda: Dynamic Data Quality with the Data Catalog
- Visit our partner page
About Alation
Alation is the leader in enterprise data intelligence solutions including data search & discovery, data governance, data stewardship, analytics, and digital transformation. Alation’s initial offering dominates the data catalog market. Thanks to its powerful Behavioral Analysis Engine, inbuilt collaboration capabilities, and open interfaces, Alation combines machine learning with human insight to successfully tackle even the most demanding challenges in data and metadata management. More than 300 enterprises drive data culture, improve decision making, and realise business outcomes with Alation including AbbVie, American Family Insurance, Cisco, Exelon, Fifth Third Bank, Finnair, Munich Re, NASDAQ, New Balance, Parexel, Pfizer, US Foods and Vistaprint. Headquartered in Silicon Valley, Alation was named to Inc. Magazine’s Best Workplaces list and is backed by leading venture capitalists including Blackstone, Costanoa, Data Collective, Dell Technologies, Icon, ISAI Cap, Riverwood, Salesforce, Sanabil, Sapphire, and Snowflake Ventures. For more information, visit alation.com
.
About Bigeye
Bigeye is the leading data observability platform designed to help data teams build trust in data. Data teams use Bigeye to instrument their data with monitoring, detect anomalies, and publish SLAs for their stakeholders to know the health of the data at all times and ensure reliable data pipelines. Complete API access, a user-friendly interface, and flexible customisation options help data teams work the way they want to. Bigeye can be deployed in as little as 15 minutes and uses automation and anomaly detection to help teams monitor all aspects of their data quality, proactively detect and resolve issues, and ensure that every user can trust the data. www.bigeye.com
About Soda
Soda is the data monitoring platform that keeps your data fit for purpose, verifiable and trustworthy. We uncover data issues, alert the right teams, and trigger resolution workflows to identify causes that impede data quality. Our open source testing projects and monitoring platform brings together data engineers, operations and the business to create trusted data. Data-driven organisations choose Soda to realise the value of their data and secure its quality. For more information, visit www.soda.io
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211207005136/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom